Abstract
The formation of amyloid fibrils from Tau is a key pathogenic feature of Alzheimer’s disease (AD). To disturb the formation of Tau aggregates is considered as a promising therapeutic strategy for AD. Recently, a natural product proanthocyanidin B2 (PB2) was confirmed to not only inhibit Tau aggregation, but also disaggregate Tau fibrils. Herein, to explore the inhibition mechanism of PB2 against Tau fibril and to provide the useful information for drug design and discovery, all-atom molecular dynamics simulations were carried out for the ordered Tau hexapeptide PHF6 oligomer in the presence and absence of PB2. The obtained result shows that PB2 can transform PHF6 oligomer from the ordered β-sheet structure into disordered one. Moreover, the clustering analysis and binding free energy calculations identify that S3 site is the most potential binding site. At S3 site, by hydrophobic and hydrogen bond interactions, the residues V309, Y310 and K311 are essential for binding with PB2, especially K311. In a word, our study reveals the molecular mechanism of PB2 inhibiting PHF6 aggregation and it will provide some valuable information for the development of Tau aggregation inhibitors.
Highlights
Alzheimer’s disease (AD), as the most common neurodegenerative disorder, is clinically distinguished by progressive declines in cognitive functions, causing severe dementia (Goedert and Spillantini, 2006)
The hydrogen bond (H-bond) number between peptides (Figure 2C) was calculated and the result shows that H-bond number of run2 and run3 of oligomer system with proanthocyanidin B2 (PB2) are obviously less than apo oligomer
We simulated PHF6 oligomer in the absence and presence of PB2 to explore the molecular mechanism of disruption of PB2 on PHF6 oligomer
Summary
Alzheimer’s disease (AD), as the most common neurodegenerative disorder, is clinically distinguished by progressive declines in cognitive functions, causing severe dementia (Goedert and Spillantini, 2006). It is the sixth leading cause of death in the United States. AD is histopathologically identified by the presence of extracellular amyloid plaques composed of amyloidbeta (Aβ) and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated Tau proteins in paired helical (PHFs) or straight filaments (SFs) (Crowther, 1991; Bloom, 2014; Götz et al, 2019). Tau hyperphosphorylation triggers neurodegeneration due to Tau propagation and aggregation into NFTs (Spillantini and Goedert, 2013). Many compounds targeting Aβ have failed to demonstrate efficacy in slowing disease progression during clinical trials
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have